Musculoskeletal Resilience in Advanced Age: Mechanisms, Clinical Insights, and Emerging Strategies

Abstract

Preserving musculoskeletal resilience in advanced age is pivotal to functional independence, quality of life, and the prevention of morbidity associated with frailty. This review synthesizes recent evidence regarding the underlying mechanisms, epidemiological trends, risk factors, clinical features, diagnostic approaches, and therapeutic strategies for maintaining musculoskeletal health in older adults. Emphasis is placed on contemporary research, guideline recommendations, and future directions, equipping clinicians with actionable insights for optimizing care in this expanding population.

Introduction

Musculoskeletal resilience, defined as the capacity of bones, muscles, joints, and connective tissues to withstand physiological stress and recover from injury, becomes increasingly critical with advancing age. Demographic shifts toward an aging population have intensified the focus on musculoskeletal health, as declines in this domain underpin frailty, disability, and institutionalization. Clinicians must understand the multifactorial determinants of musculoskeletal resilience to implement targeted interventions aimed at preserving function and reducing disease burden.

Epidemiology / Disease Burden

The global prevalence of musculoskeletal disorders rises steeply with age, with up to 70% of individuals over 65 experiencing conditions such as osteoarthritis, sarcopenia, and osteoporosis. These disorders contribute significantly to falls, fractures, chronic pain, and loss of independence. The World Health Organization projects a doubling of the geriatric population by 2050, portending a proportional increase in musculoskeletal morbidity and healthcare costs. Notably, the burden is not uniform, with disparities based on sex, ethnicity, socioeconomic status, and access to preventive care. Early identification and intervention remain essential in mitigating long-term sequelae.

Pathophysiology

Age-related musculoskeletal decline is driven by complex, interrelated mechanisms. Sarcopenia, characterized by progressive loss of skeletal muscle mass and strength, arises from a combination of reduced anabolic signaling (notably via the IGF-1/Akt/mTOR pathway), mitochondrial dysfunction, chronic low-grade inflammation (inflammaging), and neuromuscular junction degeneration. Concurrently, osteoporosis results from imbalances in bone remodeling, with increased osteoclastic resorption relative to osteoblastic formation, compounded by hormonal changes (e.g., decreased estrogen and testosterone), vitamin D deficiency, and secondary hyperparathyroidism. Connective tissue changes, including decreased collagen cross-linking and increased matrix metalloproteinase activity, further impair joint stability and tendon integrity. Collectively, these changes reduce mechanical competence and heighten susceptibility to injury.

Risk Factors

Key risk factors for diminished musculoskeletal resilience include advanced chronological age, physical inactivity, poor nutrition (notably protein insufficiency and micronutrient deficiencies), chronic comorbidities (e.g., diabetes, chronic kidney disease, rheumatoid arthritis), polypharmacy, and smoking. Genetic predisposition, prior fractures, and use of corticosteroids or other catabolic medications further increase vulnerability. Social determinants such as isolation and limited access to exercise facilities or healthcare exacerbate risk, underscoring the need for multidimensional assessment.

Clinical Features

Clinically, loss of musculoskeletal resilience manifests as decreased muscle strength (often detected via grip strength testing), reduced gait speed, impaired balance, and increased incidence of falls. Individuals may present with chronic musculoskeletal pain, joint stiffness, or overt fragility fractures. Physical examination may reveal muscle wasting, joint deformities, or tenderness. Importantly, subtle declines can precede overt disability; thus, routine screening in older adults is recommended to detect early signs and facilitate timely intervention.

Diagnosis

Diagnosis of compromised musculoskeletal resilience employs a combination of clinical assessment and objective measures. Sarcopenia is most reliably identified via dual-energy X-ray absorptiometry (DXA) for muscle mass, accompanied by functional tests such as the Short Physical Performance Battery (SPPB) and handgrip dynamometry. Osteoporosis is diagnosed based on bone mineral density (BMD) via DXA, with a T-score of ≤ -2.5 indicating disease. Laboratory evaluation may reveal secondary contributors, such as vitamin D deficiency, hyperparathyroidism, or inflammatory markers. Emerging biomarkers and imaging modalities, including high-resolution peripheral quantitative computed tomography (HR-pQCT), offer enhanced sensitivity for early detection.

Treatment & Management

Management of musculoskeletal resilience in advanced age is multidisciplinary. Resistance and balance training are foundational, with evidence supporting improvements in muscle mass, strength, and fall reduction. Nutritional interventions emphasize adequate protein intake (1.0–1.2 g/kg/day), calcium, and vitamin D supplementation. Pharmacologic therapy for osteoporosis includes bisphosphonates, denosumab, and anabolic agents such as teriparatide, tailored to fracture risk profiles. For sarcopenia, no approved pharmacotherapy exists; however, emerging agents targeting myostatin inhibition and selective androgen receptor modulators are under investigation. Pain management, occupational therapy, and fall prevention strategies are integral.

Recent Advances / Emerging Therapies

Recent advances include the development of next-generation bone anabolic therapies (abaloparatide, romosozumab), which offer dual effects on bone formation and resorption. Novel exercise modalities, such as power training and vibration therapy, show promise for augmenting muscle function in frail elders. Research on senolytic agents seeks to target cellular senescence, a key contributor to age-associated musculoskeletal decline. Additionally, digital health technologies—wearable sensors and tele-rehabilitation—are increasingly utilized for remote monitoring and personalized exercise prescription, enhancing adherence and outcomes.

Guideline Recommendations

International guidelines, such as those from the International Osteoporosis Foundation and the European Working Group on Sarcopenia in Older People (EWGSOP2), recommend routine screening for osteoporosis and sarcopenia in at-risk populations. Multimodal intervention—combining exercise, nutrition, and fracture prevention—is emphasized. For secondary prevention, fall risk assessment and home safety evaluations are advised. Pharmacologic treatment should be individualized, with ongoing monitoring for efficacy and adverse effects. Interprofessional collaboration is essential to optimize musculoskeletal health in the elderly.

Conclusion

Musculoskeletal resilience in advanced age is a cornerstone of healthy aging. Understanding the multifactorial mechanisms underlying musculoskeletal decline, recognizing modifiable risk factors, and implementing evidence-based interventions are critical for preserving independence and reducing morbidity in older adults. Ongoing research into novel therapies and digital tools promises to further enhance outcomes. Clinicians must remain vigilant in assessing and addressing musculoskeletal health as an integral component of geriatric care.